[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100259548":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":29,"id":51,"slug":29,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":29,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":29,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"R-IDARAM plus intrathecal chemotherapy","EXPERIMENTAL","Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy",[13],"Drug: R-IDARAM plus intrathecal chemotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","R-IDARAM comprised of rituximab 375 mg\u002Fm2 (day 1), idarubicin 10 mg\u002Fm2(day 2 and 3); dexamethasone 100 mg\u002Fm2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g\u002Fm2 (1 h. infusion in day 2 and 3); methotrexate 2 g\u002Fm2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.",[9],[20],"R-IDARAM plus intrathecal immuochemotherapy",[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, M.D.","STUDY_CHAIR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+861066957676",null,"qlr2007@126.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Navy General Hospital","RECRUITING","Beijing","Beijing Municipality","100048","China",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Liren Qian","Doctor","100259548",false,"NCT02657785","Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy","Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy","Inclusion criteria:\n\n* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).\n\nExclusion criteria:\n\n* Involved sites other than the brain, meninges, CSF, or the eyes.\n* Age less than 18 years or greater than 75 years.\n* Inadequate bone marrow capacity (defined as neutrophils\\\u003C1.5 ×10\\^9\u002FL, platelets \\\u003C100 ×10\\^9\u002FL, and hemoglobin level\\\u003C 8 g\u002FdL).\n* Known cause of immunosuppression (ie, HIV type I infection).\n* Any previous malignancy.\n* Creatinine clearance below 60 mL\u002Fmin.\n* Heart insufficiency (NYHA IIIB or IV).\n* Uncontrolled infection.\n* Noncompensated active pulmonary or liver disease.\n* Previously treated for PCNSL, except by corticosteroids.","ALL","18 Years","75 Years",{"count":61,"type":62},100,"ESTIMATED","INTERVENTIONAL",[65,66],"PHASE2","PHASE3","This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.",[69],"Primary Central Nervous System Lymphoma","2020-09-08",{"date":72,"type":73},"2020-09-09","ACTUAL",{"date":75,"type":29},"2010-09",{"date":77,"type":62},"2030-12",{"name":5,"class":6},1]